BCL2 and colorectal cancer: As shown in Figure 5A, regorafenib in combination with rosuvastatin synergistically promoted the expression of c-PARP/PARP, c-Caspase3/Caspase3 and Bax, but significantly downregulated Bcl-2 levels, these data collectively demonstrated that regorafenib in combination with rosuvastatin synergistically induced the apoptosis of colorectal cancer in vivo.